Mary Wilson
Well-known member
By COLUMBIA UNIVERSITY IRVING MEDICAL CENTER
NOVEMBER 10, 2020
A nasal antiviral created by researchers at Columbia University Vagelos College of Physicians and Surgeons blocked transmission of SARS-CoV-2 in ferrets, suggesting the nasal spray also may prevent infection in people exposed to the new coronavirus.
The compound in the spray—a lipopeptide developed by Anne Moscona, MD, and Matteo Porotto, PhD, professors in the Department of Pediatrics and directors of the Center for Host-Pathogen Interaction—is designed to prevent the new coronavirus from entering host cells.
... The antiviral lipopeptide is inexpensive to produce, has a long shelf life, and does not require refrigeration.
A preprint of the study appeared in bioRxiv on November 5, 2020; a paper describing a first generation of the compound and its effect in a 3D model of the human lung first appeared in the journal mBio on October 20, 2020.
https://scitechdaily.com/nasal-spray...d-to-covid-19/
NOVEMBER 10, 2020
A nasal antiviral created by researchers at Columbia University Vagelos College of Physicians and Surgeons blocked transmission of SARS-CoV-2 in ferrets, suggesting the nasal spray also may prevent infection in people exposed to the new coronavirus.
The compound in the spray—a lipopeptide developed by Anne Moscona, MD, and Matteo Porotto, PhD, professors in the Department of Pediatrics and directors of the Center for Host-Pathogen Interaction—is designed to prevent the new coronavirus from entering host cells.
... The antiviral lipopeptide is inexpensive to produce, has a long shelf life, and does not require refrigeration.
A preprint of the study appeared in bioRxiv on November 5, 2020; a paper describing a first generation of the compound and its effect in a 3D model of the human lung first appeared in the journal mBio on October 20, 2020.
https://scitechdaily.com/nasal-spray...d-to-covid-19/
Last edited: